Nautilus Biotechnology, Inc.

Nautilus Biotechnology, Inc. (Nasdaq: NAUT) is a life-sciences company developing a single-molecule protein-sequencing platform designed to enable large-scale proteomics analysis. The company became a publicly traded entity in 2021 through a business combination with Arya Sciences Acquisition Corp III, a blank-check vehicle sponsored by Perceptive Advisors. Nautilus operates in the biotechnology and life-sciences instrumentation sector, with its research-stage platform targeting the protein analysis market. The company filed an 8-K with the Securities and Exchange Commission on July 28, 2026, under accession number 0001808805-26-000030. For full filing history, financials, and SPAC-merger data on NAUT, sign up for complete access at SpacDesk.